首页> 外文期刊>Gastroenterology research and practice >Submucosal Tunnel Endoscopic Resection for Esophageal Submucosal Tumors: A Multicenter Study
【24h】

Submucosal Tunnel Endoscopic Resection for Esophageal Submucosal Tumors: A Multicenter Study

机译:食管黏膜下肿瘤的黏膜下隧道内镜切除术:多中心研究

获取原文
           

摘要

Background. Submucosal tumors (SMTs) are primarily benign tumors, but some may have a malignant potential. Endoscopic submucosal dissection that has been used for removing esophageal SMTs could cause perforation. Submucosal tunnel endoscopic resection (STER) is an improved and an effective technique for treating esophageal SMTs. Aims. This study was conducted to evaluate the efficacy and safety of STER for treating esophageal SMTs. Methods. A retrospective study design was adopted to analyze the baseline characteristics, clinical outcomes, and follow-up data of patients with esophageal SMTs, which originated from the muscularis propria layer and were treated with STER from September 2011 to May 2018. Results. A total of 119 lesions were included from 115 patients who were successfully treated with STER. The mean age of the patients was 49.7 ± 10.7 years. The lesions were primarily located in the middle and lower esophagus. The mean size of the lesions was 19.4 ± 10.0 mm. The mean operation duration was 46.7 ± 25.6 min, and the mean duration of hospitalization was 5.9 ± 2.8 days. The total en bloc resection rate and the complete resection rate were 97.5% and 100%, respectively. Regarding complications, there were 9 (7.8%) cases of perforation, 2 (1.7%) cases of pneumothorax, and 9 (7.8%) cases of subcutaneous emphysema. Histopathological results revealed 113 (95.0%) cases of leiomyoma, 5 (4.2%) cases of gastrointestinal stromal tumors, and 1 (0.8%) case of a granular cell tumor. During the mean 15-month follow-up, there were no cases of recurrence and distant metastasis. Conclusions. STER is a safe and feasible technique for treating esophageal SMTs originating from the muscularis propria layer.
机译:背景。粘膜下肿瘤(SMT)主要是良性肿瘤,但有些可能具有恶性潜能。内镜下粘膜下剥离术已被用于切除食道SMT,可能引起穿孔。粘膜下隧道内镜切除术(STER)是一种改进的有效技术,用于治疗食管SMT。目的进行这项研究以评估STER治疗食管SMT的疗效和安全性。方法。通过回顾性研究设计,分析了食管SMT患者的基线特征,临床结局和随访数据,这些患者源自2011年9月至2018年5月的固有肌层,并接受了STER治疗。 115名成功用STER治疗的患者共包括119个病变。患者的平均年龄为49.7±10.7岁。病变主要位于食道的中下部。病变的平均大小为19.4±10.0mm。平均手术时间为46.7±25.6 min,平均住院时间为5.9±2.8·天。整体切除率和完全切除率分别为97.5%和100%。在并发症方面,有9例(7.8%)穿孔,2例(1.7%)气胸和9例(7.8%)皮下气肿。组织病理学结果显示平滑肌瘤113例(95.0%),胃肠道间质瘤5例(4.2%),颗粒细胞瘤1例(0.8%)。在平均15个月的随访期间,没有复发和远处转移的病例。结论。 STER是一种治疗源自固有肌层的食管SMT的安全可行技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号